Skip to main content
OpenTrials
Completed

NCT Number: NCT00681395

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Adverse Events Pharmacokinetic

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Site Reference ID/Investigator# 8089

Orlando, Florida, 32809, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • General good health
  • BMI 19 to 29

Exclusion criteria

  • Currently enrolled in another study
  • Females who are pregnant or breastfeeding

Treatment and study plan

ABT-143

Drug

once daily for 6 days

ABT-335

Drug

once daily for six days

Rosuvastatin

Drug

Once daily for 6 days

Primary outcomes

  1. Adverse event and safety laboratory assessments

    Time frame: 7 days

  2. Pharmacokinetic parameters

    Time frame: 7 days

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2008
Primary completion
2008
First posted
May 21, 2008
Registry last updated
Sep 28, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.